Physician profile
Qingwei Robert Yan
NPI 1003995648
$13,508.14
in general payments reported to CMS, 2019-2025
47 companies · $5,733 in 2025
The $5,733 reported for 2025 was more than what 91% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $860 · 2021: $1,182 · 2022: $1,349 · 2023: $1,377 · 2024: $1,893 · 2025: $5,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,467 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,276 · Education: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,466.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,275.80 |
| Education | $260.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $3,353.53 | 2025 | |
| Astellas Pharma US INC | $2,181.09 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Abbvie INC. | $1,026.76 | 2019-2025 | Lupron Depot, Botox |
| Janssen Biotech, INC. | $1,013.85 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Sumitomo Pharma America, INC. | $858.94 | 2023-2025 | Gemtesa, Orgovyx |
| Dendreon Pharmaceuticals LLC | $539.48 | 2019-2024 | Provenge |
| Procept Biorobotics Corporation | $537.64 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Pfizer INC. | $486.39 | 2019-2025 | |
| Accord Healthcare, INC. | $429.72 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $275.92 | 2019-2024 | |
| Myriad Genetic Laboratories, INC. | $242.14 | 2021-2025 | Prolaris, Myrisk |
| Merck Sharp & Dohme LLC | $220.83 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $209.31 | 2020-2023 | Lynparza |
| Urovant Sciences INC | $180.87 | 2021-2022 | |
| Myovant Sciences INC. | $180.10 | 2021-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qingwei Yan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.